Quantcast

Latest Multi-drug-resistant tuberculosis Stories

2010-11-24 10:02:19

China had an estimated 1.3 million new cases of tuberculosis (TB) in 2008, of which 112,000 were multi-drug resistant (MDR-TB). Over the period 2001, TB was the second largest cause of death among China's 39 notifiable communicable diseases. In a Policy Forum, published in this week's PLoS Medicine, Zhong-wei Jia (Peking University) and colleagues from Beijing, China, report on how a combination of increased domestic funding, supplemented by foreign loans and donations, led to a dramatic...

2010-10-05 08:36:00

KOLKATA, India, Oct. 5 /PRNewswire/ -- Lilly MDR TB Partnership and Children International will continue a public awareness campaign aimed to bolster the eradication of tuberculosis in India. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/childreninternational/46392/ (Photo: http://photos.prnewswire.com/prnh/20101005/MM75368 ) (Photo: http://www.newscom.com/cgi-bin/prnh/20101005/MM75368 ) This highly successful program meets...

2010-09-21 14:00:00

NEW YORK, Sept. 21 /PRNewswire-FirstCall/ -- An eminent international panel of judges has selected Eli Lilly and Company (NYSE: LLY) to receive a World Business and Development Award for demonstrating what can be achieved through successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB). Lilly was chosen because the activities of The Lilly MDR-TB Partnership demonstrate a clear linkage between vital business practices and a contribution toward achieving the...

2010-09-02 06:00:00

SUNNYVALE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition. Funded and led by the Foundation for Innovative New Diagnostics...

2010-07-26 08:20:00

ROCKVILLE, Md., July 26 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: Reddy, V.M., L. Einck, K. Andries, and C.A. Nacy. In Vitro Interactions between New...

2010-06-17 14:00:00

From West Baltimore to West Africa ZARIA, Nigeria, June 17 /PRNewswire-USNewswire/ -- This week, the U.S. Centers for Disease Control (CDC) Director, Dr. Tom Frieden, visited the Nigerian National TB and Leprosy Training Center (NTBLTC) to tour a multimillion dollar laboratory complex established by the Institute of Human Virology (IHV) of the University of Maryland School of Medicine in Baltimore, Maryland, and the Institute of Human Virology-Nigeria. This U.S.-Nigeria partnership was...

2010-05-19 11:33:03

Commentary: 'Tuberculosis anywhere is tuberculosis everywhere' Tuberculosis (TB) is an enormous global public health problem. Migration and failure by governments and the public health community to adequately treat and prevent TB among migrants is an important barrier to TB control. To reduce the incidence, spread and severity of tuberculosis, government policies must ensure that all patients have easy access to diagnosis and treatment, according to a commentary entitled "TB on the Move" in...

2010-04-06 14:00:00

HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer (NYSE: PFE) to discover novel therapeutic agents to treat multi-drug resistant tuberculosis (MDR-TB). Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx's...

2010-03-30 13:58:06

DALLAS -- Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year. The good news: A type of blood pressure medication shows promise at overcoming some drug-resistant tuberculosis, at least in the laboratory. The bad news: The Mycobacterium tuberculosis bacterium, which causes the disease, might be resistant to...

2010-03-24 09:00:00

WASHINGTON, March 24 /PRNewswire-FirstCall/ -- A Senate briefing today will discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world. The briefing, Bringing Established Methods to Scale: New Perspectives in the Changing World of TB, is co-hosted by the Global Health Council, American Thoracic Society, Stop TB Partnership...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related